Prognostic Markers in Resected Non–Small-Cell Lung Cancer: An Patients with 5 Year Follow-Up

Abstract We performed a retrospective analysis of potential prognostic markers in 260 patients with surgically resected stage I and II non–small-cell lung cancer (NSCLC) with a minimum 5-year follow-up. Cox proportional hazard models and Wilcoxon tests were employed to analyze the effect of patient characteristics on survival and disease-free survival (DFS). In the univariate analysis, the following were significant predictors of shorter overall survival: N-stage (N1 vs N0) (p bcl-2 expression (positive vs negative) (p= 0.03); age (> 63.5 vs K-ras mutation, and immunohistochemistry staining for Lewis y , p53, Rb, microvessel count, HER2, E-cadherin and neuroendocrine markers did not reach statistical significance. In multivariate analysis, the following predicted for shorter overall survival: N-stage (p bcl-2 (p = 0.05); and for DFS, N-stage (p

[1]  M. Rooney,et al.  Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[3]  S. Mehdi,et al.  Prognostic significance of Lewis y antigen in resected stage I and II non-small cell lung cancer. , 1998, Chest.

[4]  W. Richards,et al.  Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Abe,et al.  Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  N. Weidner,et al.  Prognostic significance of Ki-67 immunostaining and symptoms in resected stage I and II non-small cell lung cancer. , 1998, Lung cancer.

[7]  J. V. van Noord,et al.  Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non-small cell lung cancer. , 1998, American journal of respiratory and critical care medicine.

[8]  Athens Greece,et al.  Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  M. Buyse,et al.  Immunocytochemical markers in stage I lung cancer: relevance to prognosis. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Angeletti,et al.  Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. , 1997, Journal of the National Cancer Institute.

[11]  G. Strauss.  Prognostic markers in resectable non-small cell lung cancer. , 1997, Hematology/oncology clinics of North America.

[12]  S. Graziano.  Non-small cell lung cancer: clinical value of new biological predictors , 1997 .

[13]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[14]  P. Yang,et al.  Sialomucin expression is associated with erbB-2 oncoprotein overexpression, early recurrence, and cancer death in non-small-cell lung cancer. , 1997, American journal of respiratory and critical care medicine.

[15]  A. Tatum,et al.  Blood group antigen A and flow cytometric analysis in resected early-stage non-small cell lung cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  W. Richards,et al.  Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. , 1996, The Annals of thoracic surgery.

[17]  J. Roth,et al.  Survival in early-stage non-small cell lung cancer. , 1995, The Annals of thoracic surgery.

[18]  G. Patterson,et al.  Immunostains for blood group antigens lack prognostic significance in T1 lung carcinoma. , 1995, The Annals of thoracic surgery.

[19]  J. Feramisco,et al.  Immunohistochemical evaluation of E-cadherin and epidermal growth factor receptor in non-small cell lung cancer. , 1995, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[20]  M Paesmans,et al.  Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Angeletti,et al.  Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. , 1995, British Journal of Cancer.

[22]  S. Medendorp,et al.  Expression of blood group antigen A by stage I non-small cell lung carcinomas. , 1995, The Annals of thoracic surgery.

[23]  M E Burt,et al.  Incidence of local recurrence and second primary tumors in resected stage I lung cancer. , 1995, The Journal of thoracic and cardiovascular surgery.

[24]  D. Harpole,et al.  A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. , 1995, Cancer research.

[25]  S. Piantadosi,et al.  Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience. , 1994, Chest.

[26]  S. O’Lear,et al.  The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer. , 1994, Cancer research.

[27]  S. Rodenhuis,et al.  C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. , 1994, The Journal of clinical investigation.

[28]  A. Harris,et al.  bcl-2 protein in non-small-cell lung carcinoma. , 1993, The New England journal of medicine.

[29]  J. Mate,et al.  Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. , 1993, Oncogene.

[30]  W Blumenfeld,et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.

[31]  Johnson Be,et al.  The biology of lung cancer. , 1993, Seminars in oncology.

[32]  T Takahashi,et al.  Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. , 1993, Cancer research.

[33]  C. Angeletti,et al.  Relation of neovascularisation to metastasis of non-small-cell lung cancer , 1992, The Lancet.

[34]  S. Hakomori,et al.  Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. , 1992, The New England journal of medicine.

[35]  K. Sugimachi,et al.  ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. , 1992, Cancer research.

[36]  K. Sugimachi,et al.  Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. , 1991, European journal of cancer.

[37]  H. Wieand,et al.  DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma , 1991, Cancer.

[38]  A. Sahin,et al.  Expression of blood-group antigen A--a favorable prognostic factor in non-small-cell lung cancer. , 1991, The New England journal of medicine.

[39]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[40]  S. Rodenhuis,et al.  K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.

[41]  D. Weiner,et al.  p185neu expression in human lung adenocarcinomas predicts shortened survival. , 1990, Cancer research.

[42]  K. Inoue,et al.  Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non‐small cell lung cancer , 1990, Cancer.

[43]  J. Sørensen,et al.  Prognostic factors in resected stages I and II adenocarcinoma of the lung. A multivariate regression analysis of 137 consecutive patients. , 1990, The Journal of thoracic and cardiovascular surgery.

[44]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[45]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[46]  C. Mountain,et al.  Prognostic implications of the International Staging System for Lung Cancer. , 1988, Seminars in oncology.

[47]  S. Rodenhuis,et al.  Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. , 1987, The New England journal of medicine.

[48]  P. Zimmerman,et al.  PLOIDY AS A PROGNOSTIC DETERMINANT IN SURGICALLY TREATED LUNG CANCER , 1987, The Lancet.

[49]  S. Piantadosi,et al.  Postoperative T1 N0 non-small cell lung cancer. Squamous versus nonsquamous recurrences. The Lung Cancer Study Group. , 1987, The Journal of thoracic and cardiovascular surgery.

[50]  D. Cox,et al.  Analysis of Survival Data. , 1985 .

[51]  M. Gail,et al.  Prognostic factors in patients with resected stage I non‐small cell lung cancer. A report from the Lung Cancer Study Group , 1984, Cancer.

[52]  I W Taylor,et al.  Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. , 1983, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[53]  S. Hsu,et al.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[54]  K E Stanley,et al.  Prognostic factors for survival in patients with inoperable lung cancer. , 1980, Journal of the National Cancer Institute.

[55]  L. Vindeløv,et al.  Flow microfluorometric analysis of nuclear DNA in cells from solid tumors and cell suspensions , 1977, Virchows Archiv. B, Cell pathology.

[56]  V. Ll.  Flow microfluorometric analysis of nuclear DNA in cells from solid tumors and cell suspensions. A new method for rapid isolation and straining of nuclei. , 1977 .

[57]  S. Newsom,et al.  LOCAL CHEMOTHERAPY FOR PSEUDOMONAS LUNG ABSCESS , 1974 .

[58]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .